Request Legal Help Now - Free
 

Valsartan Cancer Risk


The drug Valsartan (a generic version of Diovan), which is prescribed to treat high blood pressure and prevent heart failure, has been recalled worldwide after it was found to contain N-nitrosodimethylamine (NDMA), a known carcinogen. Valsartan contamination from a Chinese manufacturing plant may date back to 2012, potentially exposing many patients to Valsartan cancer risk, liver damage and tumors. It has been on the market for 15 years.

FREE VALSARTAN CANCER LAWSUIT EVALUATION

Send your Valsartan Cancer claim to a lawyer who will review your claim at NO COST or obligation.
GET LEGAL HELP NOW

Valsartan Carcinogen

NDMA, or N-nitrosodimethylamine, is a chemical used in rocket fuel and it is classified as a carcinogen. Short-term exposure to toxic NDMA can cause liver damage while long-term exposure can increase the risk of liver, kidney, and lung tumors. Investigators found that NDMA had contaminated Valsartan’s production at Zhejiang Huahai Pharmaceuticals in Linhai, China, possibly since 2012 when the company changed its manufacturing process and produced NDMA as a by-product.

Valsartan Recall

The FDA recall on July 17 involves medicines from: Solco Healthcare, Major Pharmaceuticals, and Teva. Valsartan-containing products made by Teva Pharmaceuticals and Prinston Pharmaceuticals Inc. are labeled as A-S Medication Solutions LLC, AvKARE and RemedyRepack, according to the FDA. Two of these companies, A-S Medication and RemedyRepack, may also distribute valsartan products not affected by the recall.

The following additional re-packagers are recalling or are expected to recall valsartan-containing products:
  • H. J. Harkins Company Inc. (this company was not originally included on either list)
  • Lake Erie Medical, doing business as Quality Care Products LLC
  • NuCare Pharmaceuticals Inc.
  • Northwind Pharmaceuticals
  • Proficient Rx
  • Bryant Ranch Prepack Inc.


Valsartan Medication

The FDA approved Valsartan as a treatment for high blood pressure, or hypertension, in adults and children age six and up. It’s also approved for use in adults to treat heart failure and to reduce the risk of death in patients who recently had a heart attack. Valsartan is in a class of hypertension medications known as angiotensin II receptor agonists that reduce the constriction of blood vessels so that blood flows more freely. Valsartan is a stand-alone medication or valsartan HCTZ, which combines valsartan with the diuretic hydrochlorothiazide.

Valsartan Lawsuits

Valsartan lawsuits allege the medication can be tainted with N-nitrosodimethylamine (NDMA), a known cancer-causing substance. Attorneys are investigating claims from clients who took valsartan and have been diagnosed with liver damage, tumors, or lung cancer.

A proposed national class action has begun in Canada on behalf of all Canadians who purchased or ingested one or more of the valsartan medications which have been recalled, according to the CBC. The plaintiff claims that five pharmaceutical companies who supplied contaminated valsartan nationwide were negligent in their manufacturing of the drugs and in their failure to implement appropriate quality control testing when they received raw material from their supplier in China. The five defendants in the proposed Valsartan class action lawsuit are Teva Canada Limited, Sandoz Canada Inc., Pro Doc Limitee, Sanis Health Inc., and Sivem Pharmaceuticals ULC.

According to Radio Canada International,(July 18, 2018) the five pharmaceutical companies involved have so far not released information on the levels of contaminant, nor the number of years the chemical was in their products, nor what the potential health implications are. One Canadian attorney said the requests for a class-action suit already have over a thousand applicants, and he expects tens of thousands more--the recall could impact 4.4 million Canadians who have been prescribed these drugs.

“The recall is huge, based on the volume and the large number of patients it could have impacted,” John Brito, of the market research firm Fore Pharma told the New York Times(July 16, 2018). If you developed cancer or liver damage after taking the medication, you may have a legal claim against Valsartan manufacturers.

Valsartan Cancer Risk Legal Help

If you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Published on Jul-31-18

VALSARTAN CANCER LEGAL ARTICLES AND INTERVIEWS

Valsartan Recall Lawsuits Filed over Alleged Carcinogenic Contaminants
Valsartan Recall Lawsuits Filed over Alleged Carcinogenic Contaminants
September 17, 2018
Washington, DC On August 27, 2018, the Food and Drug Administration published updated press information that expands its original July 17 valsartan recall notice. Sixteen companies have now announced voluntary recalls of blood pressure and heart medications READ MORE
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News

ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.
Request Legal Help Now! - Free